Principles and analytical performance of Papilloplex® HR-HPV, a new commercial CE-IVD molecular diagnostic test for the detection of high-risk HPV genotypes
Authors:
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 95 (1) , 46-54
Abstract
No abstract availableKeywords
Funding Information
- Innovate UK
This publication has 19 references indexed in Scilit:
- Continuing global improvement in human papillomavirus DNA genotyping services: The 2013 and 2014 HPV LabNet international proficiency studiesJournal of Clinical Virology, 2018
- Evaluation of a Novel Single-Tube Method for Extended Genotyping of Human PapillomavirusJournal of Clinical Microbiology, 2018
- Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the NetherlandsBMJ, 2016
- Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?Clinical Microbiology and Infection, 2015
- Cross-roads in the classification of papillomavirusesVirology, 2013
- Human papillomavirus and cervical cancerThe Lancet, 2013
- Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort studyBMJ, 2009
- The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR ExperimentsClinical Chemistry, 2009
- Prevalence of HPV Infection Among Females in the United StatesJAMA, 2007
- A Prospective Study of Age Trends in Cervical Human Papillomavirus Acquisition and Persistence in Guanacaste, Costa RicaThe Journal of Infectious Diseases, 2005